SpringerLink
Log in

Carbamazepine

  • Chapter
  • First Online:
Antiseizure Medication Interactions

  • 835 Accesses

Abstract

The pharmacokinetic characteristics of carbamazepine are described and the interaction effects of concomitant antiseizure medications on carbamazepine in terms of its pharmacokinetics and pharmacodynamics are highlighted.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now
Chapter
EUR 29.95
Price includes VAT (Germany)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 96.29
Price includes VAT (Germany)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 128.39
Price includes VAT (Germany)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Forsythe WI, Owens JR, Toothill C. Effectiveness of acetazolamide in the treatment of carbamazepine-resistant epilepsy in children. Dev Med Child Neurol. 1981;23:761–9.

    Article  CAS  Google Scholar 

  2. Stockis A, Chanteux H, Rosa M, Rolan P. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res. 2015;113:19–27.

    Article  CAS  Google Scholar 

  3. Gaston TE, Bekib EM, Cutter GR, Liu Y, Szaflarski JP, UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58:1586–92.

    Article  CAS  Google Scholar 

  4. Bialer M, Johannessen SI, Koepp MJ, Levy RH, Perucca E, Perucca P, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the fifteenth Eilat conference on new antiepileptic drugs and devices (EILAT XV). II. Drugs in more advanced clinical development. Epilepsia. 2020;61:2365–85.

    Article  CAS  Google Scholar 

  5. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication and negative myoclonus after the addition of clobazam. Epilepsia. 1998;39:1115–8.

    Article  CAS  Google Scholar 

  6. Johannessen SI, Strandjord RE, Munthe-Kaas AW. Lack of effect of clonazepam on serum levels of diphenylhydantoin, phenobarbital and carbamazepine. Acta Neurol Scand. 1977;55:506–12.

    Article  CAS  Google Scholar 

  7. Elger C, Halasz P, Maia J, Almeidas L, Soares-da-Silva P, on behalf of the BIA-2093-301 Investigators Study Group. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial seizures: a randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia. 2009;50:454–63.

    Article  CAS  Google Scholar 

  8. Almeida L, Bialer M, Soares-da-Silva P. Eslicarbazepine acetate. In: Shorvon SD, Perucca E, Engel J, editors. The treatment of epilepsy. 3rd ed. Oxford: Blackwell; 2009. p. 485–98.

    Chapter  Google Scholar 

  9. Altafullah I, Talwar D, Loewenson R, Olson K, Lockman LA. Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children. Epilepsy Res. 1989;4:72–80.

    Article  CAS  Google Scholar 

  10. Wagner ML, Remmel RP, Graves NM, Leppik IE. Effect of felbamate on carbamazepine and its metabolites. Clin Pharmacol Ther. 1993;53:536–43.

    Article  CAS  Google Scholar 

  11. Radulovic LL, Wilder BJ, Leppik IE, Bockbrader HN, Chang T, Posvar EL, Sedman AJ, Uthman BM, Erdman GR. Lack of interaction of gabapentin with carbamazepine and valproate. Epilepsia. 1994;35:155–61.

    Article  CAS  Google Scholar 

  12. Cawello W, Nickel B, Eggert-Formella A. No pharmacokinetic interaction between lacosamide and carbamazepine in healthy volunteers. J Clin Pharmacol. 2010;50:459–71.

    Article  CAS  Google Scholar 

  13. Novy J, Patsalos PN, Sander JW, Sisodiya SM. Lacosamide neurotoxicity associated with concomitant use of sodium-blocking antiepileptic drugs: a pharmacodynamic interaction? Epilepsy Behav. 2011;20:20–3.

    Article  Google Scholar 

  14. Malminiemi K, Keranen T, Kerttula T, Moilanen E, Ylitalo P. Effects of short-term lamotrigine on pharmacokinetics of carbamazepine. Int J Clin Pharmacol Ther. 2000;38:540–5.

    Article  CAS  Google Scholar 

  15. Besag FM, Berry DJ, Pool F, Newbery JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic or pharmacodynamic interaction? Epilepsia. 1998;39:183–7.

    Article  CAS  Google Scholar 

  16. Gidal BE, Baltes E, Otoul C, Perucca E. Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from the randomized clinical trials. Epilepsy Res. 2005;64:1–11.

    Article  CAS  Google Scholar 

  17. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217–9.

    Article  CAS  Google Scholar 

  18. Browne TR, Feldman RG, Buchanan RA, Allen CA, Fawcett-Vickers L, Szabo GK, Mattson GF, Norman SE, Greenblatt DJ. Methsuximide for complex partial seizures: efficacy, toxicity, clinical pharmacology, and drug interactions. Neurology. 1983;33:414–8.

    Article  CAS  Google Scholar 

  19. McKee PJW, Blacklaw J, Forrest G, Gillham RA, Walker SM, Connelly D, Brodie MJ. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol. 1994;37:27–32.

    Article  CAS  Google Scholar 

  20. Majid O, Laurenza A, Ferry J, Hussein Z. Impact of perampanel on pharmacokinetics of concomitant antiepileptics in patients with partial-onset seizures: pooled analysis of clinical trials. Br J Clin Pharmacol. 2016;82:422–30.

    Article  CAS  Google Scholar 

  21. Rambeck B, May T, Juergens U. Serum concentrations of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit. 1987;9:298–303.

    Article  CAS  Google Scholar 

  22. Summary of product characteristics: Piracetam (Nootropil). UCB Pharma Ltd. Last update 9 Feb 2017.

    Google Scholar 

  23. Brodie MJ, Wilson EA, Wesche DL, Alvey CW, Randinitis EJ, Posvar EL, Hounslow NJ, Bron NJ, Gibson GL, Bockbrader HN. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy. Epilepsia. 2005;46:1407–13.

    Article  CAS  Google Scholar 

  24. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–41.

    Article  CAS  Google Scholar 

  25. Cazali N, Tran A, Treluyer JM, Rey E, d’Athis P, Vincent J, Pons G. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56:526–36.

    Article  CAS  Google Scholar 

  26. Summary of product characteristics: Sulthiame (Ospolot). Phebra Pty, Ltd. Last update 21 Nov 2013.

    Google Scholar 

  27. Gustavson LE, Cato A, Boellner SW, Cao GX, Quian JX, Guenther HJ, Sommerville KW. Lack of pharmacokinetic drug interactions between tiagabine and carbamazepine or phenytoin. Am J Ther. 1998;5:9–16.

    Article  CAS  Google Scholar 

  28. Sachdeo RC, Sachdeo SK, Walker SA, Kramer LD, Nayak RK, Doose DR. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 1996;37:774–80.

    Article  CAS  Google Scholar 

  29. Mack CJ, Kuc S, Mulcrone SA, Pilley A, Grunewald RA. Interaction between topiramate and carbamazepine: two case reports and a review of clinical experience. Seizure. 2002;11:464–7.

    Article  CAS  Google Scholar 

  30. Pisani F, Caputo M, Fazio A, Oteri G, Russo M, Spina E, Perucca E, Bertilsson L. Interaction of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine, with valproate: a pharmacokinetic interaction. Epilepsia. 1990;31:339–42.

    Article  CAS  Google Scholar 

  31. McKee PJW, Blacklaw J, Butler E, Gillham RA, Brodie MJ. Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Res. 1992;11:193–8.

    Article  CAS  Google Scholar 

  32. Brodie MJ, Mumford JP. Double-blind substitution of vigabatrin and valproate in carbamazepine-resistant partial epilepsy. 012 Study group. Epilepsy Res. 1999;34:199–205.

    Article  CAS  Google Scholar 

  33. Sanchez-Alcaraz A, Quintana MB, Lopez E, Rodriguez I, Llopis P. Effect of vigabatrin on the pharmacokinetics of carbamazepine. J Clin Pharm Ther. 2002;27:427–30.

    Article  CAS  Google Scholar 

  34. Jedrzejczak J, Dlawichowska E, Owczarek K, Majkowski J. Effect of vigabatrin addition on carbamazepine serum levels in patients with epilepsy. Epilepsy Res. 2000;39:115–20.

    Article  CAS  Google Scholar 

  35. Ragueneau-Majlessi I, Levy RH, Bergen D, Garnet W, Rosenfeld W, Mather G, Shah J, Grundy JS. Carbamazepine pharmacokinetics are not affected by zonisamide: in vitro mechanistic study and in vivo clinical study in epileptic patients. Epilepsy Res. 2004;62:1–11.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Epilepsy, UCL Queen Square Institute of Neurology, London, UK

    Philip N. Patsalos

Authors
  1. Philip N. Patsalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip N. Patsalos .

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Patsalos, P.N. (2022). Carbamazepine. In: Antiseizure Medication Interactions. Springer, Cham. https://doi.org/10.1007/978-3-030-82790-8_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-82790-8_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-82789-2

  • Online ISBN: 978-3-030-82790-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation